Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions
- PMID: 18847554
- PMCID: PMC4366004
- DOI: 10.1016/j.vaccine.2008.06.021
Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions
Abstract
Human papillomavirus (HPV) infection is commonly found in the genital tract of men and women with or without any clinical lesion. The association of HPV DNA with several different ano-genital cancers other than cervical has been reported for the vulva, vagina, anus and penis. HPV DNA has also been identified in head and neck cancers in the oral cavity, the oropharynx and the larynx in both sexes. In men, 80-85% of anal cancers and close to 50% of penile cancers are associated with HPV infection. In women, HPV DNA is prevalent in 36-40% vulvar cancer cases and close to 90% of vaginal cancers. There is limited data available on the natural history and HPV-related diseases in the genital tract in men, although studies are ongoing. Efficacy of HPV vaccines in the prevention of HPV infection and disease among men also remains unknown. Among HPV DNA positive ano-genital cancer cases, HPV-16 is the most frequently found followed distantly by HPV-18. In benign HPV-related diseases such as genital warts or recurrent respiratory papillomatosis HPV-6 and 11, the two most frequent non-oncogenic types, are the predominant types detected. Oncogenic types are rarely detected. In this article we summarize and review studies describing the natural history of HPV infections among men and its impact on HPV related disease in women. We summarize the evidence linking HPV in the epidemiology and etiology of cancers of the vulva, vagina, anus and oropharynx and present recent estimates of the burden of and HPV type distribution in genital warts and in cases of HPV infection of the airways.
Conflict of interest statement
ARG: Advisory Board (Merck and Co., Inc); Research Grants (Merck and Co., Inc); Speakers Bureau (Merck and Co., Inc).
GT-L: Speakers Bureau (Merck Sharp and Dohme).
EF: Speakers bureau (GlakoSmithKline).
SS: Research Grants (Merck & Co. Inc., Sanofi Pasteur MSD).
SKK: Advisory Board (Sanofi Pasteur MSD); Research Grants (Merck and Co., Inc, Sanofi Pasteur MSD); Steering Committee (Merck and Co., Inc); Travel Grants (Merck and Co., Inc, Sanofi-Pasteur MSD).
NM: Advisory Board (Merck and Co., Inc, Sanofi Pasteur MSD); Speakers Bureau (Sanofi Pasteur MSD); Steering Committee (Merck and Co., Inc).
FXB: Advisory Board (GlaxoSmithKline, Merck Sharp & Dohme, Sanofi Pasteur MSD); Speakers Bureau (GlaxoSmithKline); Research Grants (Merck Sharp & Dohme, Sanofi Pasteur MSD).
Figures
References
-
- IARC. IARC Monographs on the Evaluation of carcinogenic risk to humans. Vol. 90. Lyon: IARC Press; 2007. Human Papillomavirus.
-
- Haga T, Kim SH, Jensen RH, Darragh T, Palefsky JM. Detection of genetic changes in anal intraepithelial neoplasia (AIN) of HIV-positive and HIV-negative men. J Acquir Immune Defic Syndr. 2001;26(3):256–262. - PubMed
-
- Palefsky JM. Human papillomavirus infection and anogenital neoplasia in human immunodeficiency virus-positive men and women. J Natl Cancer Inst Monogr. 1998;(23):15–20. - PubMed
-
- Palefsky JM, Holly EA, Ralston ML, Da Costa M, Greenblatt RM. Prevalence and risk factors for anal human papillomavirus infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. J Infect Dis. 2001;183(3):383–391. - PubMed
-
- Xi LF, Critchlow CW, Wheeler CM, Koutsky LA, Galloway DA, Kuypers J, et al. Risk of anal carcinoma in situ in relation to human papillomavirus type 16 variants. Cancer Res. 1998;58(17):3839–3844. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical